These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31837338)

  • 1. Efficacy of infliximab in treatment-resistant depression: A systematic review and meta-analysis.
    Bavaresco DV; Uggioni MLR; Ferraz SD; Marques RMM; Simon CS; Dagostin VS; Grande AJ; da Rosa MI
    Pharmacol Biochem Behav; 2020 Jan; 188():172838. PubMed ID: 31837338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Celecoxib Adjunct Treatment on Bipolar Disorder: Systematic Review and Meta-Analysis.
    Bavaresco DV; Colonetti T; Grande AJ; Colom F; Valvassori SS; Quevedo J; da Rosa MI
    CNS Neurol Disord Drug Targets; 2019; 18(1):19-28. PubMed ID: 30398124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.
    Yang C; Bosker FJ; Li J; Schoevers RA
    BMC Psychiatry; 2018 Sep; 18(1):279. PubMed ID: 30176835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression.
    Bekhbat M; Chu K; Le NA; Woolwine BJ; Haroon E; Miller AH; Felger JC
    Psychoneuroendocrinology; 2018 Dec; 98():222-229. PubMed ID: 30249443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory markers and treatment outcome in treatment resistant depression: A systematic review.
    Yang C; Wardenaar KJ; Bosker FJ; Li J; Schoevers RA
    J Affect Disord; 2019 Oct; 257():640-649. PubMed ID: 31357161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review.
    Sukhram SD; Yilmaz G; Gu J
    Oxid Med Cell Longev; 2022; 2022():1061274. PubMed ID: 36160713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of nitrous oxide in the treatment of major depressive disorder and treatment-resistant major depressive disorder: A systematic review and meta-analysis nitrous oxide in depressive disorders.
    Rech P; Custodio RM; Rodrigues Uggioni ML; Silveira Prestes G; Marçal F; Silveira VP; Dagostin VS; Colonetti T; Rosa MI
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Feb; 129():110869. PubMed ID: 37813146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.
    Raison CL; Rutherford RE; Woolwine BJ; Shuo C; Schettler P; Drake DF; Haroon E; Miller AH
    JAMA Psychiatry; 2013 Jan; 70(1):31-41. PubMed ID: 22945416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression.
    Olgiati P; Serretti A; Souery D; Dold M; Kasper S; Montgomery S; Zohar J; Mendlewicz J
    J Affect Disord; 2018 Feb; 227():777-786. PubMed ID: 29254066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis.
    Na KS; Lee KJ; Lee JS; Cho YS; Jung HY
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():79-85. PubMed ID: 24056287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
    Edwards SJ; Hamilton V; Nherera L; Trevor N
    Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of repetitive transcranial magnetic stimulation (rTMS) adjunctive therapy for major depressive disorder (MDD) after two antidepressant treatment failures: meta-analysis of randomized sham-controlled trials.
    Vida RG; Sághy E; Bella R; Kovács S; Erdősi D; Józwiak-Hagymásy J; Zemplényi A; Tényi T; Osváth P; Voros V
    BMC Psychiatry; 2023 Jul; 23(1):545. PubMed ID: 37501135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
    Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
    World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and acceptability of adjunctive psychological and pharmacological interventions for treatment-resistant depression: protocol for a systematic review and network meta-analysis.
    Husain MI; Strawbridge R; Carter B; Jones BDM; Young A; Carvalho AF
    BMJ Open; 2019 May; 9(5):e028538. PubMed ID: 31092667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, quality of life, and acceptability outcomes of atypical antipsychotic augmentation treatment for treatment-resistant depression: protocol for a systematic review and network meta-analysis.
    Liu Y; Zhou X; Qin B; Del Giovane C; Zhang Y; Xie P
    Syst Rev; 2014 Nov; 3():133. PubMed ID: 25373601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials.
    Goss AJ; Kaser M; Costafreda SG; Sahakian BJ; Fu CH
    J Clin Psychiatry; 2013 Nov; 74(11):1101-7. PubMed ID: 24330897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
    Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
    Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous ketamine for treatment-resistant major depressive disorder.
    Covvey JR; Crawford AN; Lowe DK
    Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study.
    Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
    Psychiatry Res; 2018 Nov; 269():207-211. PubMed ID: 30153598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.